AuthorisedTherapeutic exploratory (Phase II)Interventional

IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer

This clinical trial is for adults with stage 3 non-small cell lung cancer who have recently completed chemoradiotherapy. Researchers are studying an immunotherapy drug called Imfinzi (durvalumab) to see how well it prevents the cancer from coming back. Imfinzi works by helping your own immune system find and attack cancer cells. In this study, doctors are also using advanced blood tests known as ctDNA tests. These tests search for tiny pieces of cancer DNA floating in the bloodstream. By tracking these traces, doctors hope to better understand how well the treatment is working for each person. Participants receive the medicine through a drip into a vein and attend regular hospital visits for scans, blood tests, and health checks. Researchers will track participants' health and quality of life over at least 12 months to check how effective and safe the treatment is.

At a glance

Status

Authorised

Phase

Therapeutic exploratory (Phase II)

Sponsor

Intergroupe Francophone De Cancerologie Thoracique

Enrolment target

177

Start

02 Jul 2026

Stage III Non Small Cell Lung Cancer

What is this study about?

Stage 3 non-small cell lung cancer means the cancer has spread into nearby tissues or lymph nodes in the chest, but not to distant parts of the body. The usual treatment often involves chemoradiotherapy, which is chemotherapy combined with radiotherapy. After finishing this treatment, doctors want to do everything possible to prevent any remaining cancer cells from growing back.

This trial is testing a consolidation treatment—care given straight after initial therapy—using an immunotherapy drug called Imfinzi. Unlike traditional chemotherapy, which attacks fast-growing cells directly, immunotherapy helps your body's natural defences recognise and fight cancer cells. The main aim is to see if patients remain free of cancer growth 12 months after starting the study.

An important part of this trial is the use of ctDNA blood tests. When cancer cells break down, they shed tiny fragments of their DNA into the blood. By testing for these microscopic traces, doctors can get an early picture of whether any cancer remains, even before it might show up on a standard scan. This could help tailor treatments more closely to what each patient needs in the future.

Researchers will also closely track participants' general well-being. Patients will complete regular questionnaires about their daily activities, energy levels, and symptoms. This ensures the team understands not only how well the drug controls the cancer, but also how it affects day-to-day quality of life.

Key takeaways

Tests the immunotherapy drug Imfinzi to help keep stage 3 lung cancer from returning.
Uses special ctDNA blood tests to look for microscopic traces of cancer.
Aimed at adults who have recently finished chemoradiotherapy.
Involves regular hospital visits for infusions, scans, and health check-ups.
Participation is voluntary, and you can withdraw at any time.

Who may be eligible?

This trial is open to adults aged 18 and over who have been diagnosed with stage 3 non-small cell lung cancer. To be considered, you must have recently finished standard chemoradiotherapy treatment.

Because this study involves ongoing hospital visits and treatments, you should generally be well enough to look after yourself and manage everyday activities. Your heart, lungs, kidneys, and liver will also need to be working reasonably well.

You may not be eligible if your cancer has spread to distant parts of your body, or if you have certain active autoimmune conditions that could be worsened by immunotherapy. Your cancer doctor will review your full medical history, scans, and blood test results to confirm whether taking part is safe and suitable for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

I am 18 years of age or older.
I have been diagnosed with stage 3 non-small cell lung cancer.
I have recently finished chemoradiotherapy treatment.
I am well enough to attend regular hospital appointments and look after myself day-to-day.
I do not have an active autoimmune disease that prevents me from taking immunotherapy.

Answer every question to see your result.

What does participation involve?

Taking part involves receiving Imfinzi as an infusion (a slow drip into a vein), usually given at a hospital day clinic every few weeks. Each treatment visit typically takes a few hours, during which the care team will check your temperature, blood pressure, and overall health.

You will also have regular blood tests, including the special ctDNA tests, and routine imaging scans (such as CT scans) to see how your lungs are responding. At several points during the study, you will be asked to fill out short quality of life questionnaires about your physical symptoms and everyday feelings.

The main treatment and monitoring period lasts for at least 12 months, followed by ongoing check-ups to keep track of your long-term health. Your clinical team will give you a clear schedule before you decide to join.

Potential risks and benefits

A potential benefit of joining is receiving an immunotherapy treatment that may help prevent your cancer from returning, alongside very close monitoring from cancer specialists. However, Imfinzi can cause side effects. Common ones include fatigue, mild skin rashes, cough, or bowel changes, while less common side effects involve inflammation in organs like the lungs, liver, or thyroid. Extra clinic visits and blood tests are also required. Taking part is entirely voluntary, and you can change your mind and leave the study at any time without your regular NHS care being affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
France

Common questions

What is Imfinzi?

Imfinzi (durvalumab) is an immunotherapy medicine given through a drip into a vein. It works by unmasking cancer cells so your body's immune system can find and destroy them.

What is a ctDNA blood test?

ctDNA stands for circulating tumour DNA. It is a sensitive blood test that checks for tiny fragments of DNA shed by cancer cells into your bloodstream.

Will taking part cost me anything?

No, the trial treatment and extra study tests are provided free of charge. Some trials may also help cover travel expenses to and from the hospital.

Can I leave the study if I change my mind?

Yes, you are free to withdraw from the trial at any point. Deciding to leave will not affect your standard medical care or your relationship with your doctor.

Does this trial replace my normal cancer care?

This treatment is given as follow-on care after you have completed your initial chemoradiotherapy. It works alongside your regular specialist oncology care.